TOBREX
LOE ApproachingNDAOPHTHALMICSOLUTION/DROPS
Approved
Dec 1980
Lifecycle
LOE Approaching
Competitive Pressure
30/100
Clinical Trials
1
Data completeness
3/8 — Basic
Drug data last refreshed 20h ago · AI intelligence enriched 2w ago
AI summarySynthesized from FDA + DailyMed + ClinicalTrials.gov data
TOBREX (tobramycin) is an aminoglycoside antibiotic ophthalmic solution approved in 1980 for treating bacterial eye infections. It works by inhibiting bacterial protein synthesis and demonstrates in vitro activity against a broad spectrum of gram-positive and gram-negative ocular pathogens, including Pseudomonas aeruginosa and methicillin-resistant Staphylococci. The product is indicated for dry eye and is administered topically as drops.
$0.057MPart D
LOE ApproachingTOBREX is nearing loss of exclusivity with minimal Part D engagement (257 claims, $57K spending), indicating a mature, declining commercial opportunity with reduced team investment likelihood.
Mechanism of Action
Mechanism of action data is being enriched from DailyMed and FDA sources. Check back soon for updated drug intelligence.
Indications
Indication data is being enriched from DailyMed and FDA labeling. Check back soon for approved therapeutic uses.
Clinical Trials (1)
Tobradex BID Compared to TOBRADEX and TOBREX/Vehicle
Started Dec 2006
0Post-surgical Inflammation
Career Relevance
TOBREX positions are primarily post-exclusivity and maintenance-focused, offering limited career growth in an aging, low-velocity commercial environment. Roles are concentrated in cost management and generic transition rather than growth or innovation.
Generic Product Manager
Worked on TOBREX at Novartis? Share your interview experience or compensation data (+7 days Pro)
Data Sources
- Drug label: DailyMed / FDA
- Clinical trials: ClinicalTrials.gov
- Patent data: FDA Orange Book
- Spending data: CMS Medicare
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.